Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Clean Hands Accessible and Manageable for Patients (CHAMPs)
NCT05866393
Recruiting
This study proposes the novel use of a bedrail-affixed technology-based patient hand hygiene system with verbal and visual reminders to improve hospitalized older adults' self-management of hand hygiene practice, which in return reduces harmful germs found on older adult's hands that lead to infections.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/02/2025
Locations: Lous Stokes Cleveland VA Medical Center, Cleveland, Ohio
Conditions: Pathogen Transmission, Patient Participation, Aging
Register for Updates
Obeticholic Acid for Prevention in Barrett's Esophagus
NCT04939051
Recruiting
This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibrotic effects mediated by FXR activation. It down regulates bile acid availability and decreases proinflammatory cytokine production including IL-1beta and TNFalpha in human enterocytes and immune cells. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Register for Updates
Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy
NCT04888988
Recruiting
This phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual approach for treating CIPN is treatment with drugs that help reduce symptoms of other types of neuropathy (for example, from diabetes). However, these drugs do not treat all symptoms of CIPN. Exercise may help to reduce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Strecker Cancer Center-Belpre, Belpre, Ohio
Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
NCT04709705
Recruiting
A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: The Ohio State Univ. Wexner Medical Center, Columbus, Ohio
Conditions: Cardiac Surgery
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Implant for Walking After Incomplete SCI
NCT06965127
Recruiting
This is a device study that will evaluate the effect of an implanted stimulator on improving walking in people with incomplete spinal cord injury. There are two phases in the study: 1) Screening - this phase determines if the individual is a good candidate to receive an implanted system, 2) Implantation, controller development, and evaluation - this phase includes implanting the device and setting the individual up for system use, creating controllers for walking, and evaluating the effect of th... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/01/2025
Locations: Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio
Conditions: Spinal Cord Injury (SCI), Gait
Register for Updates
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
NCT06754046
Recruiting
The goal of this clinical trial is to learn if retropubic midurethral sling (RP-MUS) or bulkamide injection (PAHG) at the time of pelvic organ prolapse repair is better from the patient's perspective. The main questions it aims to answer are: What is the average difference in the urogenital distress inventory (UDI) long form score 24 months after surgery for each procedure? Which procedure has the fewest complications and lowest short- and long-term morbidity profile? Participants will: Be bl... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Stress Urinary Incontinence, Vaginal Prolapse
Register for Updates
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT05987644
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Lung Cancer, NSCLC, Brain Metastases
Register for Updates
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT05896189
Recruiting
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: Cleveland Clinic Akron General, Akron, Ohio
Conditions: Breast Cancer, Cognitive Impairments
Register for Updates
CMV CTLs in Neonates With CMV Infection
NCT05564598
Recruiting
Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened. All patients will receive treatment with valganciclovir or ganciclovir. There is a safety run in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2 for randomization to receive antiviral therapy with or without CMV CTLs. Funding source: FDA OOPD
Gender:
ALL
Ages:
Between 0 days and 21 days
Trial Updated:
05/01/2025
Locations: Nationwide Children's Hosptial, Columbus, Ohio
Conditions: Congenital Cytomegaloviral (CMV) Disease
Register for Updates
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
NCT05551936
Recruiting
This study is planned as a single arm clinical trial of tazemetostat in combination with bendamustine and rituximab with both a phase I and phase II component. All patients will receive tazemetostat twice daily on days 1-28 in combination with bendamustine 90 mg/m2 IV on days 1 and 2 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up to three cycles. Following this, patients will receive tazemetostat twice daily on days 1-28 and rituximab 375 mg/m2 IV on day 1 of a 28-day cycle for up... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Follicular Lymphoma
Register for Updates
Neuroimaging Reveals Treatment-related Changes in DLD
NCT05268341
Recruiting
Children with developmental language disorders (DLD, aka specific language impairment), a prevalent pediatric disorder, experience hallmark grammar deficits with life-long impacts on educational and occupational outcomes. While effective and early interventions can mitigate the impact of DLD, not enough is known about the neural basis of DLD in young children, yet is needed to inform the design of more individualized interventions. This project uses neuroimaging, along with behavioral methods, w... Read More
Gender:
ALL
Ages:
Between 48 months and 71 months
Trial Updated:
05/01/2025
Locations: New Horizon Childcare, Cincinati, Ohio
Conditions: Developmental Language Disorder
Register for Updates